



JC14 Rec'd PCT/PTO 18 DEC 2001

PATENT #20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Peter David DAVIS

International Application No.: PCT/GB00/00503

International Filing Date: 15 FEBRUARY 2000

Priority Date: 16 FEBRUARY 1999

For: SUBSTITUTED STILBENE COMPOUNDS WITH VASCULAR DAMAGING ACTIVITY  
Attorney Docket No.: U013588-9


Assistant Commissioner for Patents  
Washington, D.C. 20231

**REQUEST FOR CORRECTION OF NOTIFICATION OF MISSING  
REQUIREMENTS**

The Notification of Missing Requirements mailed on October 11, 2001 (copy enclosed) indicates that a copy of the "Sequence Listing" in computer readable form has not been submitted.

Applicants note that this application does not disclose any nucleotide and/or amino acid sequence. Therefore, the requirement is issued in error and the "Sequence Listing" is not due.

Respectfully submitted,

  
JOHN RICHARDS  
LADAS & PARRY  
26 WEST 61<sup>ST</sup> STREET  
NEW YORK, NY 10023  
REG. NO:31,053(212)708-1915

**CERTIFICATION UNDER 37 C.F.R. 1.10\***

*(Express Mail label number is mandatory.)*

*(Express Mail certification is optional.)*

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on this date October 22, 2001, in an envelope as "Express Mail Post Office to Addressee," Mailing Label Number EV01108798US addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

  
CONNIE YANNOTTI

*(type or print name of person mailing paper)*

Signature of person mailing paper

**WARNING:** Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).  
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.


<small>Commissioner for Patents, Inc. PCT, United States Patent and Trademark Office, Washington, D.C. 20531, www.uspto.gov</small>		
---	--	--

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/890,990	Peter David Davis	U 013588-9

00140  
 LADAS & PARRY  
 26 WEST 61ST STREET  
 NEW YORK, NY 10023

INTERNATIONAL APPLICATION NO.	
PCT/GB00/00503	
I.A. FILING DATE	PRIORITY DATE
02/15/2000	02/16/1999

**CONFIRMATION NO. 1813**  
**371 FORMALITIES LETTER**



Date Mailed: 10/11/2001

### NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Request for Immediate Examination

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- \$130 Surcharge for providing the oath or declaration later than the appropriate 30 months months from the priority date (37 CFR 1.492(e)) is required.
- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason (s):
  - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
  - APPLICANT MUST PROVIDE:

- An initial or substitute computer readable form (CRF) of the "Sequence Listing."
  - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
    - For Rules Interpretation, call (703) 308-4216
    - To Purchase PatentIn Software, call (703) 306-2600
    - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

**ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

**SUMMARY OF FEES DUE:**

Total additional fees required for this application is **\$130** for a Large Entity:

- **\$130** Late oath or declaration Surcharge.

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

BARBARA A CAMPBELL

Telephone: (703) 305-3631

**PART 1 - ATTORNEY/APPLICANT COPY**

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/890,990	PCT/GB00/00503	U 013588-9

**Bayer Corporation**  
**100 Bayer Road**  
**Pittsburgh, PA 15205-9741**

**RECEIVED**


**DEC 26 2001**

**PCT INITIAL PROCESSING**

**FIRST CLASS**

**JC14 Rec'd PCT/PTO 18 DEC 2001**

*09/914,984*



**ASSISTANT COMMISSIONER FOR PATENTS**  
**Washington, D.C. 20231**

